Sales in Asia and Oceania are expected to grow 18.6%  year on year, to ¥68.7 billion. Excluding the impact of for- eign exchange rates, we forecast an approximately 18%  increase. Continued growth in sales of such products as  Prograf, Vesicare and MyCAMINE is expected. In addition to anticipated global sales growth for  XTANDI, sales of OAB treatments Vesicare and Betanis/ Myrbetriq/BETMIGA are forecasted to grow. Although sales  of Prograf are expected to decline in the Americas and  Japan, Prograf sales in Asia and Oceania are expected to  expand, with global sales projected to remain level with the  previous fiscal year. Sales of Harnal, on the other hand, are  expected to decline mainly due to the impact of generics. Sales in Japan are expected to decrease by 0.4% year  on year to ¥528.4 billion. Sales in the Japanese market are  expected to decline by 1.4% year on year to ¥508.3 billion.  The impact of the NHI drug price revision enforced in April  2014 is expected to be offset by sales of growing products  and new products. Consequently, we forecast that the  year-on-year decrease in domestic sales of ethical pharma- ceuticals will be slight. Contributions to sales are expected  from Suglat, which we launched in April 2014, and XTANDI,  which we launched in May 2014. We also forecast expan- sion in sales of growing products such as Celecox and new  products such as Cimzia in addition to increased sales of  the OAB treatments Vesicare and Betanis. On the other  hand, sales are forecasted to decline for products such as  Lipitor, Gaster, Myslee and Seroquel, mainly due to the  impact of generics. In the Americas, we forecast a 0.8% year-on-year  increase in sales, to ¥289.2 billion. Sales on a U.S. dollar  basis are expected to increase 1.0% year on year, to  US$2,892 million. In addition to XTANDI, overall sales of  the OAB treatments VESIcare and Myrbetriq and income  from Tarceva are forecasted to continue growing. On the  other hand, we anticipate a decrease in sales of Prograf and  overall sales of the pharmacologic stress agents Adenoscan  and Lexiscan, mainly due to the impact of generics. In EMEA, we forecast a 15.6% year-on-year increase in  sales, to ¥305.6 billion. Sales on a euro basis are expected  to increase 11.0% year on year, to  € 2,183 million. In addi- tion to XTANDI, sales of products including the OAB treat- ments Vesicare and BETMIGA are forecasted to grow.  Although we expect sales of Prograf through the Company’s  own distribution channel to decrease on a local currency  basis, we anticipate the revenues we receive from this to  increase on a yen basis as a result of the foreign exchange  impact. Sales of Harnal through the Company’s own distribution channel are forecasted to decrease. As of March 31, 2014, Astellas worldwide employed  17,649 people, a year-on-year increase of 195. The total  number of Medical Representatives (MRs) was approxi- mately 6,340, a year-on-year decrease of about 10. In  Japan, we had 8,082 employees, down 71 from the previ- ous year-end. In the Americas, the regional head count  was 2,883 employees, down 97 from the previous year- end. In EMEA, we had 4,580 employees, up 224 year on  year. In Asia and Oceania, we had 2,104 employees, up  139 from the previous year-end. As a result, we forecast an 11.7% year-on-year  increase in core operating profit to ¥208.0 billion. Core  profit for the year is expected to increase 16.0% year on  year to ¥154.0 billion. We project a 3.4% increase in R&D expenses to ¥198.0  billion, with a ratio of R&D expenses to sales of 16.6%  (compared with 16.8% in fiscal 2013). Gross profit is expected to increase due to growing sales,  as well as a decrease in the cost of sales ratio as a result of  changes in product mix and other factors. SG&A expenses are expected to increase due to  increases in selling expenses related to co-promotion of  XTANDI in the U.S. and expenses related to sales of new  products. Core Operating Profit and Core Profit for the Year Number of Employees Number of Employees by Geographical Area Financial Section 99 Annual Report 2014 _  Astellas Pharma Inc.  (persons) 2013.3 2014.3 Total 17,454 17,649 Japan 8,153 8,082 Americas 2,980 2,883 EMEA 4,356 4,580 Asia & Oceania 1,965 2,104